Term
| DMARD- Need periodic eye exams (esp if >40 years old) to check for retinal damage; least toxic overall of DMARDs and least costly to monitor; can take up to a year to see clinical efficacy |
|
Definition
|
|
Term
| DMARD- causes urine discoloration |
|
Definition
|
|
Term
| DMARD- most predictable benefit, Pregnancy category X, Avoid AlOH |
|
Definition
|
|
Term
| May be used intraarticular to minimize SE if only a few joints are affects; Some major SE: increased appetite/weight gain, diabetes, HTN, osteoporosis, impaired wound healing and increased infection rate |
|
Definition
|
|
Term
| Can be used with ASA, NSAIDs and low dose corticosteroids and off-label with MTX; Black Box: Pregnancy and hepatotoxicity SE: diarrhea, alopecia, nausea, rash |
|
Definition
|
|
Term
| Black Box Warning: infection risk (serious fungal, bacterial, and viral), lymphoma/malignancy (esp in children and adolescents); need to evaluate pts for TB, CHF; no live vaccines |
|
Definition
|
|
Term
| IV infusion; extreme caution in CHF; black box: infection risk, neoplastic disease |
|
Definition
|
|
Term
| Dosed SC; Black Box: evaluated for latent TB infection prior to therapy, infection ris, neoplastic disease; CI: active chronic or local infections |
|
Definition
|
|
Term
| Precautions/warnings: infection risk, potential for new onset cancer, get immunizations early/avoid live vaccines; Pegylated fab fragment |
|
Definition
|
|
Term
| See doc IMMEDIATELY if any signs of infections (pt can die from opportunistic infections that aren't address right away); seek medical attention if experience wt loss, persistent fever, sweating, cough, SOB, or fatigue |
|
Definition
|
|
Term
| Tends to be 2nd line; injection site rxns, HA, N/D, neutropenia; CI hypersensitivity to E. coli |
|
Definition
|
|
Term
| Black box: increased risk of serious infections; recombinant humanized mAb that binds specifically IL6R; no concurrent live vaccines |
|
Definition
|
|
Term
| Given as 30 min IV infusion on weeks 2 and 4 and q 4 weeks after that. Also given SC. Weight-based dosing. |
|
Definition
|
|
Term
| Anti-CD20 mAb; 2 IV infusions separated by 2 weeks then every 24 weeks; black box: infusion rxn, tumor lysis syndrome, severe mucocutaneous rxns, progressive multifocal leukoencephalopathy |
|
Definition
|
|
